The release noted that brepocitinib demonstrated consistent benefits in preventing treatment failure across key subgroups, ...
Brepocitinib 45 mg once-daily achieved statistically significant benefit compared to placebo on the primary and all key secondary endpoints for each of CLARITY-1 and CLARITY-2, the two identical Phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results